Eurizon Capital SGR S.p.A. increased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,022,406 shares of the company’s stock after buying an additional 161,643 shares during the period. Johnson & Johnson accounts for about 1.4% of Eurizon Capital SGR S.p.A.’s holdings, making the stock its 12th largest holding. Eurizon Capital SGR S.p.A.’s holdings in Johnson & Johnson were worth $536,956,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $28,000. Matrix Trust Co grew its holdings in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC grew its holdings in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after purchasing an additional 55 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several research reports. Bank of America restated a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $283.69 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1-year low of $193.45 and a 1-year high of $286.08. The company has a market capitalization of $682.93 billion, a price-to-earnings ratio of 42.98, a PEG ratio of 2.77 and a beta of 0.22. The business has a 50-day moving average of $266.83 and a 200-day moving average of $249.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.
More Johnson & Johnson News
Here’s some of the latest news about JNJ:
- Positive Sentiment: J&J reported favorable Phase 3 results for CAPLYTA in adults with bipolar I disorder, with the drug providing rapid relief of manic symptoms. Positive data could strengthen the case for expanding the medicine’s use and future sales. Johnson & Johnson Reports Favorable Data For Bipolar Study
- Positive Sentiment: The company is backing Francis Medical as it advances its Vanquish water-vapor therapy device for prostate cancer through the FDA premarket approval process. J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. The deals broaden its potential reach in cancer care and psychiatry, though both carry development and regulatory risk. J&J leads Francis Medical investment to fund prostate cancer device Johnson & Johnson backs new cancer device and leads $100 million depression bet
- Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
